Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

Overview

It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 3, 2023

Detailed Description

This study was a single-center prospective study to collect blood and skin tissue at the time of consultation with a patient with non-segmental vitiligo, psoriasis, atopic dermatitis or alopecia areata, in order to better understand and compare blood and skin immune response in chronic inflammatory skin disorders: psoriasis, alopecia areata, atopic dermatitis and vitiligo.

Interventions

  • Biological: Blood samples
    • Blood samples: serum and PBMC
  • Biological: Skin biopsies
    • These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.

Arms, Groups and Cohorts

  • vitiligo
    • Patients aged 18 to 75 years with non-segmental vitiligo;
  • psoriasis
    • Patients aged 18 to 75 years with plaque psoriasis;
  • atopic dermatitis
    • Patients aged 18 to 75 years with atopic dermatitis;
  • alopecia areata
    • Patients aged 18 to 75 years with alopecia areata sclerosis;

Clinical Trial Outcome Measures

Primary Measures

  • Description of the phenotype and function of blood and skin T-cell in chronic inflammatory skin disorders: psoriasis, vitiligo, atopic dermatitis, alopecia areata
    • Time Frame: Day 1
    • Description of the phenotypic analysis of cutaneous T-cell and blood of vitiligo patients evaluated by flow cytometry

Participating in This Clinical Trial

Inclusion Criteria

  • Patients aged 18 to 75 years; – Patients with non-segmental vitiligo; – Patients with plaque psoriasis; – Patients with atopic dermatitis; – Patients with alopecia areata sclerosis; – written consent, free, informed and signed by the patient and the investigator (before any examination required by the study); – Subject affiliated or beneficiary of a social security system. Exclusion Criteria:

  • Patients with segmental vitiligo – Patients under local treatment (topical corticosteroid-Calcineurin inhibitor) for less than two weeks. – Patients on therapy, systemic treatments: acitretin, methotrexate, cyclosporine, Apremilast, infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, dupilumab) for less than 4 weeks. – Pregnant or breastfeeding women – Patient (e) under guardianship – Patient (e) Non-affiliated (e) a social protection

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Bordeaux
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Julien SENESCHAL, MD, PhD, Principal Investigator, University Hospital, Bordeaux
  • Overall Contact(s)
    • Julien SENESCHAL, MD,PhD, +335 56 79 49 63, julien.seneschal@chu-bordeaux.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.